SCHEMBL4954971

SCHEMBL4954971

CS(=O)(=O)c1ccc(-c2csc(N(Cc3ccc(NC(=O)C(=O)O)c(C(=O)O)c3)c3ccc(Cl)c(Cl)c3)n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.48
GCGR P47871 11/20 0.44
GIPR P48546 10/20 0.44
ENPP2 Q13822 1/20 0.39
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
POLB P06746 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
RORC P51449 1/20 0.38
PTPRB P23467 1/20 0.38
EIF4E P06730 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4957463 0.77 GCGR (0.42) GCGRGIPRENPP2MEN1NPC1
SCHEMBL4957460 0.77 GCGR (0.42) GCGRGIPRENPP2MEN1NPC1
SCHEMBL4954649 0.77 PTPN1 (0.49) PTPN1GCGRGIPRMEN1NPC1
SCHEMBL4957179 0.75 GCGR (0.42) PTPN1GCGRGIPRMEN1NPC1
SCHEMBL4956664 0.74 GCGR (0.51) GCGRGIPRMEN1NPC1RAB9A
SCHEMBL4957045 0.74 PTPN1 (0.45) PTPN1GCGRGIPR
SCHEMBL4956655 0.73 GCGR (0.56) GCGRGIPRMEN1NPC1RAB9A
SCHEMBL6154899 0.73 GCGR (0.57) GCGRGIPRMEN1NPC1RAB9A
SCHEMBL6154238 0.71 GCGR (0.56) GCGRGIPRMEN1KMT2A
SCHEMBL4957017 0.71 GCGR (0.44) PTPN1GCGRGIPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200371-A1 THIAZOLE AND THIADIAZOLE INHIBITORS OF TYROSINE PHOSPHATASES IMPINJ, INC. 2008-08-21 US claimed
US-20060194768-A1 Thiazole and thiadiazole inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2006-08-31 US claimed
US-20080200371-A1 THIAZOLE AND THIADIAZOLE INHIBITORS OF TYROSINE PHOSPHATASES IMPINJ, INC. 2008-08-21 US disclosed
US-7381736-B2 Thiazole and thiadiazole inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-06-03 US disclosed
EP-1841749-A1 DERIVATIVES OF THIAZOLE AND THIADIAZOLE INHIBITORS OF TYROSINE PHOSPHATASES Metabasis Therapeutics, Inc. (US) 2007-10-10 EP disclosed
US-20060194768-A1 Thiazole and thiadiazole inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2006-08-31 US disclosed
WO-2006028970-A1 DERIVATIVES OF THIAZOLE AND THIADIAZOLE INHIBITORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194768-A1 Thiazole and thiadiazole inhibitors of tyrosine phosphatases PTPN1, PTPN5, PTPN18 PTPN1 1/4885GCGR 2166/4885GIPR 1774/4885
US-20080200371-A1 THIAZOLE AND THIADIAZOLE INHIBITORS OF TYROSINE PHOSPHATASES PTPN1, PTPN5, PTPN18 PTPN1 1/4885GCGR 2166/4885GIPR 1774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.